Ursula Johanna Buchholz

Ursula Johanna Buchholz

Auto-generated profile, based on publicly available information

Ursula Johanna Buchholz

RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
UBUrsula J. Buchholz
Ursula J. Buchholz
ABAlexander Bukreyev
Alexander Bukreyev
LYLijuan Yang
Lijuan Yang
ELElaine W. Lamirande
Elaine W. Lamirande
BMBrian R. Murphy
Brian R. Murphy
PCPeter L. Collins
Peter L. Collins
We investigated the contributions of the structural proteins of severe acute respiratory syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3. This vector provided direct immunization of the respiratory tract, the major site of SARS transmission, replication, and disease. The BHPIV3/SARS recombinants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high level of pulmonary SARS-CoV replication. A single intranasal administration of BHPIV3 expressing the SARS-CoV spike protein (S) induced a high titer of SARS-CoV-neutralizing serum antibodies, only 2-fold less than that induced by SARS-CoV infection. The expression of S with the two other putative virion envelope proteins, the matrix M and small envelope E proteins, did not augment the neutralizing antibody response. In absence of S, expression of M and E or the nucleocapsid protein N did not induce a detectable serum SARS-CoV-neutralizing antibody response. Immunization with BHPIV3 expressing S provided complete protection against SARS-CoV challenge in the lower respiratory tract and partial protection in the upper respiratory tract. This was augmented slightly by coexpression with M and E. Expression of M, E, or N in the absence of S did not confer detectable protection. These results identify S among the structural proteins as the only significant SARS-CoV neutralization antigen and protective antigen and show that a single mucosal immunization is highly protective in an experimental animal that supports efficient replication of SARS-CoV.

14 May 2019 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
GAGaya Amarasinghe
Gaya Amarasinghe
MAMaría Angeles Ayllón
María Angeles Ayllón
YBYiming Bao
Yiming Bao
CBChristopher F Basler
Christopher F Basler
SBSina Bavari
Sina Bavari
Jens H. KuhnJens H. Kuhn
Jens H. Kuhn

4 September 2020 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
Jens H. KuhnJens H. Kuhn
Jens H. Kuhn
SAScott Adkins
Scott Adkins
DADaniela Alioto
Daniela Alioto
SASergey Alkhovsky
Sergey Alkhovsky
GAGaya Amarasinghe
Gaya Amarasinghe
XZXueping Zhou
Xueping Zhou

1 December 2004 in Journal of Virology
Verified
Journal Article
Open access
PDF file
SBStephane Biacchesi
Stephane Biacchesi
MSMario H. Skiadopoulos
Mario H. Skiadopoulos
LYLijuan Yang
Lijuan Yang
ELElaine W. Lamirande
Elaine W. Lamirande
KTKim C. Tran
Kim C. Tran
UBUrsula J. Buchholz
Ursula J. Buchholz
Human metapneumovirus (HMPV) has recently been identified as a significant cause of serious respiratory tract disease in humans. In particular, the emerging information on the contribution of HMPV to pediatric respiratory tract disease suggests that it will be important to develop a vaccine against this virus for use in conjunction with those being developed for human respiratory syncytial virus and the human parainfluenza viruses. A recently described reverse genetic system (S. Biacchesi, M. H. Skiadopoulos, K. C. Tran, B. R. Murphy, P. L. Collins, and U. J. Buchholz, Virology 321:247-259, 2004) was used to generate recombinant HMPVs (rHMPVs) that lack the G gene, the SH gene, or both. The ΔSH, ΔG, and ΔSH/G deletion mutants were readily recovered and were found to replicate efficiently during multicycle growth in cell culture. Thus, the SH and G proteins are not essential for growth in cell culture. Apart from the absence of the deleted protein(s), the virions produced by the gene deletion mutants were similar by protein yield and gel electrophoresis protein profile to wild-type HMPV. When administered intranasally to hamsters, the ΔG and ΔSH/G mutants replicated in both the upper and lower respiratory tracts, showing that HMPV containing F as the sole viral surface protein is competent for replication in vivo. However, both viruses were at least 40-fold and 600-fold restricted in replication in the lower and upper respiratory tract, respectively, compared to wild-type rHMPV. They also induced high titers of HMPV-neutralizing serum antibodies and conferred complete protection against replication of wild-type HMPV challenge virus in the lungs. Surprisingly, G is dispensable for protection, and the ΔG and ΔSH/G viruses represent promising vaccine candidates. In contrast, ΔSH replicated somewhat more efficiently in hamster lungs compared to wild-type rHMPV (20-fold increase on day 5 postinfection). This indicates that SH is completely dispensable in vivo and that its deletion does not confer an attenuating effect, at least in this rodent model.

1 October 2005 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
SBStephane Biacchesi
Stephane Biacchesi
QPQuynh N. Pham
Quynh N. Pham
MSMario H. Skiadopoulos
Mario H. Skiadopoulos
BMBrian R. Murphy
Brian R. Murphy
PCPeter L. Collins
Peter L. Collins
UBUrsula J. Buchholz
Ursula J. Buchholz
Recombinant human metapneumovirus (HMPV) in which the SH, G, or M2 gene or open reading frame was deleted by reverse genetics was evaluated for replication and vaccine efficacy following topical administration to the respiratory tract of African green monkeys, a permissive primate host. Replication of the ΔSH virus was only marginally less efficient than that of wild-type HMPV, whereas the ΔG and ΔM2-2 viruses were reduced sixfold and 160-fold in the upper respiratory tract and 3,200-fold and 4,000-fold in the lower respiratory tract, respectively. Even with the highly attenuated mutants, there was unequivocal HMPV replication at each anatomical site in each animal. Thus, none of these three proteins is essential for HMPV replication in a primate host, although G and M2-2 increased the efficiency of replication. Each gene-deletion virus was highly immunogenic and protective against wild-type HMPV challenge. The ΔG and ΔM2-2 viruses are promising vaccine candidates that are based on independent mechanisms of attenuation and are appropriate for clinical evaluation.

1 June 2005 in Journal of Virology
Verified
Journal Article
Open access
PDF file
UBUrsula J. Buchholz
Ursula J. Buchholz
SBStephane Biacchesi
Stephane Biacchesi
QPQuynh N. Pham
Quynh N. Pham
KTKim C. Tran
Kim C. Tran
LYLijuan Yang
Lijuan Yang
PCPeter L. Collins
Peter L. Collins
The M2 gene of human metapneumovirus (HMPV) contains two overlapping open reading frames (ORFs), M2-1 and M2-2. The expression of separate M2-1 and M2-2 proteins from these ORFs was confirmed, and recombinant HMPVs were recovered in which expression of M2-1 and M2-2 was ablated individually or together [rΔM2-1, rΔM2-2, and rΔM2(1+2)]. Each M2 mutant virus directed efficient multicycle growth in Vero cells. The ability to recover HMPV lacking M2-1 contrasts with human respiratory syncytial virus, for which M2-1 is an essential transcription factor. Expression of the downstream HMPV M2-2 ORF was not reduced when translation of the upstream M2-1 ORF was silenced, indicating that it is initiated separately. The rΔM2-2 mutants exhibited a two- to fivefold increase in the accumulation of mRNA, normalized to the genome template, suggesting that M2-2 has a role in regulating RNA synthesis. Replication and immunogenicity were tested in hamsters. Animals infected intranasally with rΔM2-1 or rΔM2(1+2) did not have recoverable virus in the lungs or nasal turbinates on days 3 or 5 postinfection and did not develop HMPV-neutralizing serum antibodies or resistance to HMPV challenge. Thus, M2-1 appears to be essential for significant virus replication in vivo. In animals infected with rΔM2-2, virus was recovered from only 1 of 12 animals and only in the nasal turbinates on a single day. However, all of the animals developed a high titer of HMPV-neutralizing serum antibodies and were highly protected against challenge with wild-type HMPV. The HMPV rΔM2-2 virus is a promising and highly attenuated HMPV vaccine candidate.